(C) 2009 American Institute of Physics. [doi: 10.1063/1.3240203]“
“Headache is the most frequent presenting symptom of cerebral venous thrombosis (CVT), most commonly associated with other manifestations. It has been described as its only clinical presentation
in 15 % of patients. There is no typical pattern of headache in CVT. The objective of this study was to study the characteristics of headache as the sole manifestation of CVT. From a prospective study of 30 consecutive patients diagnosed with CVT over 18 months, we selected those who presented with headache only: they had a normal neurological Momelotinib clinical trial examination, no papilloedema and no blood or any parenchymal lesion on CT scan. All were submitted to a systematic etiological workup and a structured questionnaire about the characteristics of headache was provided. Headache was the sole manifestation of CVT in 12 patients; it was diffuse or bilateral in the majority. Seven patients referred worsening with sleep/lying down, Valsalva maneuvers or straining. There was no association
between the characteristics AG-014699 cost of headache and extension of CVT. Time from onset to diagnosis was significantly delayed in these patients presenting only with headache. In our series, 40 % of patients presented only with headache. There was no uniform pattern of headache apart from being bilateral. There was a significant delay of diagnosis in these patients. Some characteristics of headache should raise the suspicion of CVT: recent persistent headache, thunderclap headache or pain worsening with straining,
sleep/lying down or Valsalva maneuvers even in the absence of papilloedema or focal signs.”
“Background: Prior studies have yielded inconsistent results on bradyarrhythmias requiring a permanent pacemaker (PPM) after cardiac transplant. This study evaluated the predictors for PPM requirement, long-term outcomes, and influence of implant timing and device programming on prognosis after cardiac transplant.
Methods: This study NU7441 prospectively evaluated 1,307 recipients from 1985 to 2007 at Cleveland Clinic by structured follow-up and compared the outcomes of patients with and without bradyarrhythmias requiring PPM after transplantation. The primary end point was all-cause mortality or retransplant.
Results: Recipients, aged 50 +/- 15 years (donors, 33 +/- 14 years), were monitored 82 +/- 59 months, with PPM indicated in 106 (8.1%), including 61 (57.5%) early and 44 (42.5%) late. Biatrial technique strong]), predicted PPM requirement (OR [odds ratio], 2.61; 95% confidence interval [CI], 1.63-4.20; p < 0.001), and survival/retransplant outcomes were comparable between those with early, late, and no PPM requirement: 5-year primary event-free rate was 80.4% (early) vs 72.6% (late; p = 0.480) and 80.4% (early) vs 73.2% (none, p = 0.550) and 72.6% (late) vs 73.2% (none; p = 0.960). Excess atrial fibrillation was noted among PPM recipients (PPM, 12.3% vs no PPM, 6.3%; p = 0.02) with high initial DDD programming in 92.